Development of a Dosage Form of the New Antitumor Antibiotic Olivamide

Methods for selective chemical modification of the antitumor antibiotic olivomycin A(OA) were developed at GINA. The compound olivamide with advantages over starting OA was selected from series of OA analogs. The goal of the present work was to develop a dosage form of the antitumor semi-synthetic antibiotic olivamide that guaranteed the stability and high specific activity of olivamide drug substance and was designed for further comprehensive preclinical studies.